Rekombinanter ErbB2/Her2 (Pertuzumab Biosimilar) Antikörper
Reaktivität: Human
FACS, in vivo
Wirt: Maus
Monoclonal
unconjugated
Recombinant Antibody
-
- Target Alle ErbB2/Her2 (Pertuzumab Biosimilar) Produkte
- ErbB2/Her2 (Pertuzumab Biosimilar)
- Antikörpertyp
- Recombinant Antibody
- Reaktivität
- Human
-
Wirt
- Maus
-
Klonalität
- Monoklonal
-
Konjugat
- Dieser ErbB2/Her2 (Pertuzumab Biosimilar) Antikörper ist unkonjugiert
- Applikation
- Flow Cytometry (FACS), In vivo Studies (in vivo)
- Verwendungszweck
- Pertuzumab Biosimilar, Human HER2 Monoclonal Antibody
- Spezifität
- The monoclonal antibody pertuzumab biosimilar specifically binds to the human HER2/ErbB-2/c-neu.
- Produktmerkmale
- Recombinant humanized IgG1 Monoclonal Antibody.
- Aufreinigung
- Protein A affinity column
- Reinheit
- > 95% by SDS-PAGE under reducing conditions and HPLC.
- Sterilität
- 0.2 μm filtered
- Endotoxin-Niveau
- < 1 EU per 1 mg of the protein by the LAL method.
- Immunogen
- The monoclonal antibody pertuzumab biosimilar was produced in the pertuzumab biosimilar CHO stable cell line.
- Isotyp
- IgG1 kappa
-
-
- Applikationshinweise
- ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by pertuzumab.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- 1 mg/mL
- Buffer
- PBS, pH 7.4, no stabilizers or preservatives.
- Konservierungsmittel
- Without preservative
- Handhabung
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
- Haltbarkeit
- 12 months
-
- Target
- ErbB2/Her2 (Pertuzumab Biosimilar)
- Abstract
- ErbB2/Her2 (Pertuzumab Biosimilar) Produkte
- Substanzklasse
- Biosimilar
- Hintergrund
- Pertuzumab, a humanized monoclonal antibody, inhibits HER dimerization and is used for the treatment of HER2-positive metastatic breast cancer, in combination with trastuzumab and docetaxel. By binding to HER2, Pertuzumab inhibits the dimerization of HER2 with other HER receptors, resulting in slowed tumor growth.
-
Sie sind hier:
